AUTL

Autolus Therapeutics plc ADR (AUTL) | Rumor.io

Autolus Therapeutics

AUTL

Attention (50-day avg)0%

Attention rank (50-day avg)#1,155

Bullish sentiment (50-day avg)80%

Price to earnings ratio-1.72

Market capitalization495.1M

Earnings per share-1.06

Dividend yield (TTM)—

Revenue (annual)75.4M

Net income (annual)-287.5M

Social

What share of all stock conversation is about AUTL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% 0	0% 0

Sep 9

* The FDA has granted RMAT (Regenerative Medicine Advanced Therapy) designation to Autolus' obe-cel for systemic lupus and lupus nephritis treatment.
* This designation is a positive sign for the ACR 2026 abstract results, expected to be released mid-September, and suggests the FDA is willing to engage in closer regulatory interaction.
* Autolus' Q2 2026 earnings call revealed a strong foundation for the rest of the year, with the CEO citing a jump in registrations in Q1 due to positive real-world ROCCA data, and expecting continued activity and demand despite some fluctuations.

Generated by AI

Sentiment

Of the messages about AUTL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	37.5% -62.5	48% -52	72.83% -6.11	79.08% -0.48
Bearish	62.5% new	52% new	27.17% +6.11	20.92% +0.48

Bullish· Aug 19

The stock is experiencing a change in perception that can last longer, with the potential for another 100% increase in value.
The company's Q2 earnings have led to a significant increase in retail buyers and modest profit takers, with momentum buyers also entering the market.
The stock's fundamentals are strong, with a 119% YoY increase in net product revenue and a gross margin jump to 55% in Q2, indicating a real inflection and not just top-line growth.

Bearish· May 18

The biotech sector is experiencing a downturn, with Autolus Therapeutics plc ($AUTL) being particularly affected, losing $70 million per quarter.
A large sell wall of 53K shares at $1.92 has been established, which could lead to further price declines.
The company's market capitalization ($600M+) may not be justified by its early positive gross margin (GM) and manufacturing advantage (MAK) effect, potentially warranting a re-rating downward.

Generated by AI

Topics

Of the messages about AUTL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	55.56%	83.11%
Technical Analysis	—	0%	35.35%	8.83%
Earnings	—	0%	7.07%	4.97%
Analysts	—	100%	2.02%	2.51%
Controversies	—	0%	0%	0.25%
Macro	—	0%	0%	0.34%

Announcements· Aug 3

Autolus Therapeutics plc (AUTL) has achieved its year-end target of 80 active treatment centers in the US 5 months ahead of schedule, according to its Q1 2026 earnings report.
AUTL has issued a warrant to Perceptive Advisors to purchase up to 3.5 million ADSs at an exercise price of $1.9314 per ADS, and has secured a five-year credit facility with Perceptive Advisors worth up to $250 million to support future growth initiatives.
AUTL reports preliminary Q2 2026 net product revenue of approximately $45 million with a gross margin near 35%, and lifts FY 2026 sales guidance to $140–$150 million, while also announcing a strategic credit arrangement with Perceptive Advisors.

Technical Analysis· Nov 8

$AUTL is in a bullish pennant formation, close to breaking out to the upside, and holding above 7.13 may lead to a move up into the 8s.
A triple bottom formation has been identified in $AUTL, making the author increasingly bullish.
$AUTL is in a solid trend break, with a possible reversal off the lows and a potential move higher, with a price target of $10.

Generated by AI

Community

Of the messages about AUTL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	97.56%	89.03%	75.33%
Newcomers	0%	2.44%	10.97%	24.67%

Regulars· Sep 9

The FDA has granted RMAT designation to Autolus Therapeutics' obe-cel for systemic lupus and lupus nephritis, which is a positive sign for the company's pipeline expansion into autoimmune diseases.
The RMAT designation will help support Autolus' single-arm trial for obe-cel, allowing discussion of one adequate study plus confirmatory evidence, and enabling accelerated approval on a surrogate endpoint.
Autolus' Q2 2026 earnings call highlighted a sequential dip in revenue from Q1, partly due to a jump in registrations in the second half of Q1 after positive real-world ROCCA data, with the company expecting continued activity and demand, but with some elements of fluctuations between quarters.

Newcomers· Aug 11

The company's Q2 2026 earnings report shows a 119% YoY increase in AUCATZYL net product revenue, reaching $45.7M.
The report also highlights a gross margin of 55% and raised guidance for 2026 net product revenue to a range of $140-$150M.
The share price rose to $2.35, with a 13.5% gain, amid growing enthusiasm for cell therapy developments and clinical progress in biotech.

Generated by AI

On August 11, Autolus Therapeutics (NASDAQ:AUTL) reported second-quarter results that finally showed the kind of growth investors had been waiting years to see. Net product revenue hit $45.7 million, up 119% from $20.9 million a year earlier and up from $26.2 million just one quarter prior. Management used the momentum to raise full-year 2026 guidance […]

18d agoYahoo Finance

Autolus receives FDA regenerative medicine designation for obe-cel

21d agoInvesting.com

Autolus Therapeutics Earnings Call Highlights Growth Momentum

Tipranks Press Release.

1mo agoThe Globe and Mail

Exclusive BAC Article: Autolus Therapeutics; ACR November 2026 Meeting Data Obe-Cel R/R SLE, AUTO8 Candidate Results Amyloidosis End Of 2026, And Catalysts (NASDAQ:AUTL)

1mo agoSeeking Alpha

Autolus (AUTL) Q2 2026 Earnings Call Transcript

Motley Fool Press Release.

1mo agoThe Globe and Mail

Wells Fargo Gives a Buy Rating to Autolus Therapeutics (AUTL)

Detailed price information for Autolus Therapeutics Plc ADR (AUTL-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Also Discussed

Investors talking about AUTL also mention

#	Name	Attention
1	Cabaletta Bio Inc.CABA	0%0
2	PSTX - Poseida Therapeutics, Inc.	——
3	Mereo BioPharma Group plc ADRMREO	0.01%-0.01
4	IDEAYA Biosciences Inc.IDYA	0%0
5	BPMC - Blueprint Medicines Corporation	——
6	Bicycle Therapeutics plc - ADRBCYC	0%0
7	Immatics N.V.IMTX	0%0
8	Vaxcyte Inc.PCVX	0%0
9	Century Therapeutics IncIPSC	0%0
10	Fate Therapeutics Inc.FATE	0%new

Autolus Therapeutics plc ADR

Healthcare
Biotechnology

Autolus Therapeutics plc ADR is a clinical-stage biopharmaceutical company focused on developing programmed T-cell therapies for cancer and autoimmune diseases. The company applies modular cell-engineering technologies to design autologous T-cell treatments intended to recognize and eliminate diseased cells while overcoming the defenses of target tumors. Its current portfolio includes AUCATZYL, an approved therapy for adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, along with multiple pipeline programs addressing hematologic malignancies, solid tumors, and autoimmune conditions. Autolus Therapeutics plc ADR plays a specialized role in the cell-therapy market, combining research, manufacturing, and commercialization capabilities in advanced immuno-oncology and next-generation gene-modified medicines.

Website

Location

The Mediaworks

London, W12 7FP

United Kingdom

Social

What share of all stock conversation is about AUTL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% 0	0% 0

Sep 9

* The FDA has granted RMAT (Regenerative Medicine Advanced Therapy) designation to Autolus' obe-cel for systemic lupus and lupus nephritis treatment.
* This designation is a positive sign for the ACR 2026 abstract results, expected to be released mid-September, and suggests the FDA is willing to engage in closer regulatory interaction.
* Autolus' Q2 2026 earnings call revealed a strong foundation for the rest of the year, with the CEO citing a jump in registrations in Q1 due to positive real-world ROCCA data, and expecting continued activity and demand despite some fluctuations.

Generated by AI

Sentiment

Of the messages about AUTL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	37.5% -62.5	48% -52	72.83% -6.11	79.08% -0.48
Bearish	62.5% new	52% new	27.17% +6.11	20.92% +0.48

Bullish· Aug 19

The stock is experiencing a change in perception that can last longer, with the potential for another 100% increase in value.
The company's Q2 earnings have led to a significant increase in retail buyers and modest profit takers, with momentum buyers also entering the market.
The stock's fundamentals are strong, with a 119% YoY increase in net product revenue and a gross margin jump to 55% in Q2, indicating a real inflection and not just top-line growth.

Bearish· May 18

The biotech sector is experiencing a downturn, with Autolus Therapeutics plc ($AUTL) being particularly affected, losing $70 million per quarter.
A large sell wall of 53K shares at $1.92 has been established, which could lead to further price declines.
The company's market capitalization ($600M+) may not be justified by its early positive gross margin (GM) and manufacturing advantage (MAK) effect, potentially warranting a re-rating downward.

Generated by AI

Topics

Of the messages about AUTL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	55.56%	83.11%
Technical Analysis	—	0%	35.35%	8.83%
Earnings	—	0%	7.07%	4.97%
Analysts	—	100%	2.02%	2.51%
Controversies	—	0%	0%	0.25%
Macro	—	0%	0%	0.34%

Announcements· Aug 3

Autolus Therapeutics plc (AUTL) has achieved its year-end target of 80 active treatment centers in the US 5 months ahead of schedule, according to its Q1 2026 earnings report.
AUTL has issued a warrant to Perceptive Advisors to purchase up to 3.5 million ADSs at an exercise price of $1.9314 per ADS, and has secured a five-year credit facility with Perceptive Advisors worth up to $250 million to support future growth initiatives.
AUTL reports preliminary Q2 2026 net product revenue of approximately $45 million with a gross margin near 35%, and lifts FY 2026 sales guidance to $140–$150 million, while also announcing a strategic credit arrangement with Perceptive Advisors.

Technical Analysis· Nov 8

$AUTL is in a bullish pennant formation, close to breaking out to the upside, and holding above 7.13 may lead to a move up into the 8s.
A triple bottom formation has been identified in $AUTL, making the author increasingly bullish.
$AUTL is in a solid trend break, with a possible reversal off the lows and a potential move higher, with a price target of $10.

Generated by AI

Community

Of the messages about AUTL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	97.56%	89.03%	75.33%
Newcomers	0%	2.44%	10.97%	24.67%

Regulars· Sep 9

The FDA has granted RMAT designation to Autolus Therapeutics' obe-cel for systemic lupus and lupus nephritis, which is a positive sign for the company's pipeline expansion into autoimmune diseases.
The RMAT designation will help support Autolus' single-arm trial for obe-cel, allowing discussion of one adequate study plus confirmatory evidence, and enabling accelerated approval on a surrogate endpoint.
Autolus' Q2 2026 earnings call highlighted a sequential dip in revenue from Q1, partly due to a jump in registrations in the second half of Q1 after positive real-world ROCCA data, with the company expecting continued activity and demand, but with some elements of fluctuations between quarters.

Newcomers· Aug 11

The company's Q2 2026 earnings report shows a 119% YoY increase in AUCATZYL net product revenue, reaching $45.7M.
The report also highlights a gross margin of 55% and raised guidance for 2026 net product revenue to a range of $140-$150M.
The share price rose to $2.35, with a 13.5% gain, amid growing enthusiasm for cell therapy developments and clinical progress in biotech.

Generated by AI

Autolus Therapeutics

Social

Sep 9

Bullish· Aug 19

Bearish· May 18

Announcements· Aug 3

Technical Analysis· Nov 8

Regulars· Sep 9

Newcomers· Aug 11

AUCATZYL Sales Are Exploding, But Autolus (AUTL) Still Isn’t In The Black

Autolus receives FDA regenerative medicine designation for obe-cel

Autolus Therapeutics Earnings Call Highlights Growth Momentum

Exclusive BAC Article: Autolus Therapeutics; ACR November 2026 Meeting Data Obe-Cel R/R SLE, AUTO8 Candidate Results Amyloidosis End Of 2026, And Catalysts (NASDAQ:AUTL)

Autolus (AUTL) Q2 2026 Earnings Call Transcript

Wells Fargo Gives a Buy Rating to Autolus Therapeutics (AUTL)

Also Discussed

Autolus Therapeutics plc ADR

Company Information

Location

AUCATZYL Sales Are Exploding, But Autolus (AUTL) Still Isn’t In The Black

Autolus receives FDA regenerative medicine designation for obe-cel

Autolus Therapeutics Earnings Call Highlights Growth Momentum

Exclusive BAC Article: Autolus Therapeutics; ACR November 2026 Meeting Data Obe-Cel R/R SLE, AUTO8 Candidate Results Amyloidosis End Of 2026, And Catalysts (NASDAQ:AUTL)

Autolus (AUTL) Q2 2026 Earnings Call Transcript

Wells Fargo Gives a Buy Rating to Autolus Therapeutics (AUTL)

Also Discussed

Social

Sep 9

Bullish· Aug 19

Bearish· May 18

Announcements· Aug 3

Technical Analysis· Nov 8

Regulars· Sep 9

Newcomers· Aug 11